NEW YORK (GenomeWeb News) – Diagnostics developer Asuragen said today that is has received accreditation as a CLIA-compliant lab by the College of American Pathologists (CAP).

The Austin, Texas-based firm said that the CAP accreditation is "a crucial step" in its plans to begin commercializing its miRNA-based oncology and clinical sample testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.